EN DE
Watch Mangoceuticals, Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Mangoceuticals, Inc (MGRX) fair value: what the stock is really worth

As of Oct 30, 2026: fair value (intrinsic value) of Mangoceuticals, Inc stock $0.03, price $0.23, upside -89.1%, quality 17 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

MI Mangoceuticals, Inc logo Thin data Oct 30, 2026

Mangoceuticals, Inc

MGRX · US
Very expensive, weak quality

Our calculation puts a fair price 89% below what the stock costs today.

Expensive Growth (revenue 3y +270.9 %/yr in USD)
Revenue last quarter 59% below a year ago.
Fair value $0.0255 · Strongly overvalued (−89.1%)
Quality 17/100
Negative free cash flow
Trails peers (1/7)
Narrow moat 6/100 · thin data
Thin data
⚠ Dilution
Watch Mangoceuticals, Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$60.00 $0.1620 Fair Value $0.0255 Mar 2023 Oct 2026

White line = price, green steps = our fair value per fiscal year. As of Oct 30, 2026.

How to read this chart

43‑month range $0.1620 – $60.00 · fair‑value band $0.0170 – $0.0340 · the $0.2334 price screens above the $0.0255 fair value. As of Oct 30, 2026.

Follow Mangoceuticals in your weekly email

Every Wednesday you see whether Mangoceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Mangoceuticals, Inc. engages in the development, marketing, and sale of various men's wellness products and services through a telemedicine platform in the United States.

Show moreShow less

The company offers erectile dysfunction products under the Mango brand; hair loss products under the Grow brand; hormone balance and therapy products under the Mojo brand; and weight loss products under the Slim brand.

It also provides oral testosterone undecanoate to treat low testosterone in men and as a form of testosterone replacement therapy under the Prime brand; and access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations.

In addition, the company markets and sells its products online through its website www. MangoRX.com. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.

Stock analysis

Mangoceuticals, Inc (MGRX) currently trades at $0.2334, while our model-based Fair Value estimate is $0.0255, 89.1% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 92/100, which puts the data coverage at low.

Scenario range: $0.0170 (bear) to $0.0340 (bull), the price of $0.2334 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 17/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Mangoceuticals, Inc reported revenue of $456K in FY2025 versus $8.9K in FY2022, a compound +270.9%/yr. Reported net income was −$20.6M in FY2025.

Key figures

Market cap $5.7M Micro · P/S ratio 17.9 · EPS (TTM) $−1.02 · Return on equity −95.1% · Return on assets (EBIT) −265% · Operating margin −1,502% · Revenue (TTM) $315K · Revenue growth (YoY) −59.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 89% below its 52-week high and 44% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 4% fair-value upside, at −89%, MGRX screens richer than that median.

Fair Value models

Bear $0.0170 Fair Value $0.0255 Bull $0.0340
Price $0.2334 · Upside -89.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $0.0200 $0.0300 $0.0400 52
All 1 models by family
Asset-Based
NCAV (Graham) $0.0200 $0.0300 $0.0400 52

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 17/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 9
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 58
Debt, balance sheet and risk of trouble
Investment 33
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Momentum 1
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−26.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+270.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−22,279.7% (2022) → −4,200.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

MGRX screens overvalued: fair value 89% below the price. Compare with Veeva Systems Inc →

Compare Mangoceuticals, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 123 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 17 · Bottom 25%
Fair Value upside −90.0% · Bottom 25%
Profitability
Return on assets −128.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −59.1% · Bottom 25%

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/B 0.37× · Cheapest 25%
P/S (12 months) 17.93× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Veeva Systems Inc VEEV $310.34 $341.37 +10% vs MGRX
HealthEquity, Inc HQY $101.36 $111.50 +10% vs MGRX
Doximity, Inc DOCS $34.25 $37.68 +10% vs MGRX
Inventurus Knowledge Solutions Limited IKS ₹1,703 ₹1,873 +10% vs MGRX
Waystar Holding WAY $28.02 $29.10 +4% vs MGRX
Winning Health Technology Group 300253 ¥7.10 ¥3.44 −52% vs MGRX
Hinge Health, Inc HNGE $113.90 $51.25 −55% vs MGRX
BrightSpring Health Services, Inc BTSG $58.36 $25.86 −56% vs MGRX
Pro Medicus Limited PME A$196.00 A$85.12 −57% vs MGRX
Privia Health Group PRVA $22.00 $5.52 −75% vs MGRX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Mangoceuticals, Inc · Fair Value
$0.0255 −89%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Mangoceuticals, Inc Fair Value". https://www.fairvalue-calculator.com/stock/MGRX

Frequently asked questions

Is Mangoceuticals, Inc (MGRX) overvalued or undervalued?
As of Oct 30, 2026, our model estimates a fair value of $0.0255 versus a price of $0.2334, about −89% upside (overvalued).
What is the fair value of MGRX?
Our model-based fair value for Mangoceuticals, Inc is $0.0255 (as of Oct 30, 2026), built from audited fundamentals. The current price: $0.2334.
What is the quality score of MGRX?
Mangoceuticals, Inc has a Quality Score of 17/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Mangoceuticals, Inc (MGRX)?
Our model-based price target is the fair value of $0.0255 (as of Oct 30, 2026) from 1 valuation models. Cautious scenario $0.0170, optimistic scenario $0.0340. It is a calculation from audited fundamentals, not an analyst target.
What is the Mangoceuticals, Inc stock forecast for 2026?
Our models put fair value at $0.0255, about −89% upside versus a price of $0.2334 (overvalued). Cautious scenario $0.0170, optimistic scenario $0.0340. The calculation is refreshed regularly with new filings.
What is the revenue of Mangoceuticals, Inc (MGRX)?
Mangoceuticals, Inc reported trailing-twelve-month revenue of about $315K (latest available figure, as of Oct 30, 2026).
What is the intrinsic value of Mangoceuticals, Inc (MGRX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Mangoceuticals, Inc it is $0.0255 per share (as of Oct 30, 2026), against a price of $0.2334. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Mangoceuticals, Inc stock overvalued or undervalued in 2026?
As of Oct 30, 2026, MGRX trades above its calculated fair value: price $0.2334, fair value $0.0255, a gap of about −89% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MGRX?
No. The price is what the market pays today ($0.2334); the fair value is what the company's own numbers justify ($0.0255). For Mangoceuticals, Inc the two are $0.2079 per share apart. That gap is exactly why we show both numbers side by side.
How much is Mangoceuticals, Inc worth?
The market values Mangoceuticals, Inc at about $5.7M (market capitalisation, as of Oct 30, 2026). Per share that is $0.2334; our models calculate a fair value of $0.0255 per share.
What do the bullish and bearish scenarios say about MGRX?
Our models span a range for Mangoceuticals, Inc: cautious scenario $0.0170, base $0.0255, optimistic $0.0340 per share (as of Oct 30, 2026, price $0.2334). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Mangoceuticals, Inc (MGRX)?
Balance-sheet figures for Mangoceuticals, Inc (as of Oct 30, 2026): return on equity −95.1%. They feed the Quality Score of 17/100, which measures business quality independently of the share price.
How far is MGRX from its 52-week high?
Mangoceuticals, Inc trades at $0.2334, about 89% below its 52-week high of $2.21 and 44% above the low of $0.1620 (as of Oct 30, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0255 is for.
Which stocks are comparable to Mangoceuticals, Inc?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Mangoceuticals, Inc stock attractive at the current price?
The data as of Oct 30, 2026: price $0.2334, calculated fair value $0.0255 (−89%), Quality Score 17/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of MGRX calculated?
We run Mangoceuticals, Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0255, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Mangoceuticals, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Mangoceuticals, Inc (MGRX)?
The closing price on Oct 30, 2026 was $0.2334. Our model-based fair value is $0.0255, about −89% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Mangoceuticals, Inc right now?
The price sits above even our optimistic bull case ($0.0340). The favourable scenario is already priced in. Weak quality (17/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.0170 to $0.0340) leaves room in how you read the outcome.

Key figures of Mangoceuticals, Inc

How large is the market capitalisation of Mangoceuticals, Inc (MGRX)?
The market capitalisation of Mangoceuticals, Inc is $5.7M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Mangoceuticals, Inc (MGRX)?
The price-to-sales ratio of Mangoceuticals, Inc is 17.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Mangoceuticals, Inc (MGRX)?
Earnings per share at Mangoceuticals, Inc are $−1.02. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Mangoceuticals, Inc (MGRX)?
The return on equity (ROE) of Mangoceuticals, Inc is −95.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Mangoceuticals, Inc (MGRX)?
On an EBIT basis the return on assets of Mangoceuticals, Inc is −265% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Mangoceuticals, Inc (MGRX)?
The operating margin of Mangoceuticals, Inc is −1,502% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Mangoceuticals, Inc (MGRX)?
Revenue at Mangoceuticals, Inc is growing −59.1% versus a year earlier (3y avg +271%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Mangoceuticals, Inc (MGRX) generate?
The free cash flow of Mangoceuticals, Inc is −$5.9M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Mangoceuticals, Inc (MGRX) hold?
Mangoceuticals, Inc holds more cash than debt, $1.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Mangoceuticals, Inc in the live analysis

One click puts Mangoceuticals, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.